Open Payments

California Pacific Medical Center

Type
Teaching hospital
Where
San Francisco, CA
Medicare CCN
050047
Received
$1,844,215 in 230 records, 2020 ($59,019 general, $1,785,196 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2020General payment8$59,019
2020Research payment222$1,785,196

By company

CompanyRecordsAmountYears
Gilead Sciences, Inc.39$851,4312020
Merck Sharp & Dohme LLC50$400,1542020
Genentech, Inc.60$264,7872020
Intercept Pharmaceuticals, Inc.9$53,2672020
Amgen Inc.10$42,9422020
Jenavalve Technology, Inc.1$41,4652020
Takeda Pharmaceuticals U.S.A., Inc.11$35,5392020
Novocure Inc.3$29,8112020
ARRAY BIOPHARMA INC6$16,7342020
Orion Corporation3$15,4922020
Stryker Corporation4$14,4002020
Medtronic Vascular, Inc.3$13,8002020
MITSUBISHI TANABE PHARMA DEVELOPMENT AMERICA, INC.1$11,8002020
PFIZER INC.6$8,8612020
Astellas Pharma Global Development2$6,2112020
Eli Lilly and Company1$5,6742020
Mallinckrodt Hospital Products Inc.1$5,0502020
Gyrus ACMI, Inc.2$5,0002020
F. Hoffmann-La Roche AG3$5,0002020
Vanda Pharmaceuticals Inc.3$4,6732020
Aesculap, Inc.3$3,1542020
Roche Products Limited1$2,9612020
Penumbra, Inc.2$1,8502020
VIVUS LLC3$1,2432020
Allergan, Inc.1$1,2312020
Spiration, Inc.1$9922020
CSL Behring1$6872020

By nature of payment

NatureRecordsAmount
Research payment222$1,785,196
Compensation for services other than consulting, including serving as faculty or as a speaker at a v1$41,465
Space rental or facility fees (teaching hospital only)4$14,400
Gift3$3,154

Records

DateCompanyAmountNatureFormProductStudyYear
2020-12-30Merck Sharp & Dohme LLC$4,838Research paymentCash or cash equivalentMK-7339 Drug, ONCOLOGYA Phase 2 Study of Olaparib in Combination with Pembrolizumab in Participants with Previously Treated, Homologous Recomb2020
2020-12-24Intercept Pharmaceuticals, Inc.$22,562Research paymentCash or cash equivalentOCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY10118662020
2020-12-23Gilead Sciences, Inc.$8,979Research paymentCash or cash equivalentA Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilof2020
2020-12-22Merck Sharp & Dohme LLC$11,013Research paymentCash or cash equivalentLENVIMA Drug, ONCOLOGYA Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib Versu2020
2020-12-21Merck Sharp & Dohme LLC$39,083Research paymentIn-kind items and servicesLENVIMA Drug, ONCOLOGYA Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib Versu2020
2020-12-21Merck Sharp & Dohme LLC$2,139Research paymentIn-kind items and servicesLENVIMA Drug, ONCOLOGYA Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib Versu2020
2020-12-21Genentech, Inc.$572Research paymentCash or cash equivalentNon-Covered Product Drug, NonePHASE III IPATASERTIB PLUS ABIRATERON IN MCRPC 1ST LINE2020
2020-12-18Medtronic Vascular, Inc.$650Research paymentCash or cash equivalentCoreValve Evolut Device, Transcatheter Valve SystemsOptimize Pro2020
2020-12-18Genentech, Inc.$572Research paymentCash or cash equivalentAvastin Biological, BioOncologyA PHASE III OPEN LABEL RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF ATEZOLIZUMAB IN COMB2020
2020-12-17Merck Sharp & Dohme LLC$773Research paymentIn-kind items and servicesLENVIMA Drug, ONCOLOGYA Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib Versu2020
2020-12-17Intercept Pharmaceuticals, Inc.$185Research paymentCash or cash equivalentOCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY10118662020
2020-12-17Intercept Pharmaceuticals, Inc.$179Research paymentCash or cash equivalentOCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY10118662020
2020-12-16ARRAY BIOPHARMA INC$1,550Research paymentCash or cash equivalentBRAFTOVI Drug, ONCOLOGYA PHASE 2 OPENLABEL RANDOMIZED MULTICENTER TRIAL OF ENCORAFENIB BINIMETINIB EVALUATING A STANDARDDOSE AND A HIGHDOSE RE2020
2020-12-16Genentech, Inc.$130Research paymentCash or cash equivalentHerceptin Biological, BioOncologyPERJETA SAFETY STUDY IN NEO ADJUVANT BC2020
2020-12-14Genentech, Inc.$3,300Research paymentCash or cash equivalent DrugPH 1A SAD OF GDC 0134 IN ALS PATIENTS2020
2020-12-14Genentech, Inc.$1,428Research paymentCash or cash equivalentNon-Covered Product Drug, NonePHASE III IPATASERTIB PLUS ABIRATERON IN MCRPC 1ST LINE2020
2020-12-11Genentech, Inc.$1,500Research paymentCash or cash equivalent DrugPHII IL22FC ANTI ST2 IN SEVERE COVID 19 PNEUMONIA2020
2020-12-11ARRAY BIOPHARMA INC$650Research paymentCash or cash equivalentBRAFTOVI Drug, ONCOLOGYA PHASE 2 OPENLABEL RANDOMIZED MULTICENTER TRIAL OF ENCORAFENIB BINIMETINIB EVALUATING A STANDARDDOSE AND A HIGHDOSE RE2020
2020-12-10Aesculap, Inc.$1,730GiftCash or cash equivalent2020
2020-12-10Aesculap, Inc.$824GiftCash or cash equivalent2020
2020-12-10Aesculap, Inc.$600GiftCash or cash equivalent2020
2020-12-09Merck Sharp & Dohme LLC$19,739Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYPhase II study of olaparib in combination with pembrolizumab in patients with advanced melanoma with homologous recombin2020
2020-12-09Genentech, Inc.$1,000Research paymentCash or cash equivalentNon-Covered Product Drug, NoneABIRATERONE PLUS GDC 0068 OR GDC 0980 IN CRPC2020
2020-12-04Genentech, Inc.$7,040Research paymentCash or cash equivalentNon-Covered Product Drug, NoneGDC0068 COMB W TAXOTERE OR FOLFOX2020
2020-12-03Stryker Corporation$3,600Space rental or facility fees (teaching hospital only)Cash or cash equivalentNONE Device, NONE2020
2020-12-03Stryker Corporation$3,600Space rental or facility fees (teaching hospital only)Cash or cash equivalentNONE Device, NONE2020
2020-12-03Stryker Corporation$3,600Space rental or facility fees (teaching hospital only)Cash or cash equivalentNONE Device, NONE2020
2020-12-03Stryker Corporation$3,600Space rental or facility fees (teaching hospital only)Cash or cash equivalentNONE Device, NONE2020
2020-12-03Genentech, Inc.$1,223Research paymentCash or cash equivalentNon-Covered Product Drug, NoneTENECTEPLASE IN STROKE PATIENTS BETWEEN 4 5 AND 24 HOURS2020
2020-12-03Merck Sharp & Dohme LLC$1,200Research paymentCash or cash equivalentLENVIMA Drug, ONCOLOGYA Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib Versu2020
2020-12-02Merck Sharp & Dohme LLC$36,576Research paymentIn-kind items and servicesMK-7339 Drug, ONCOLOGYPhase II study of olaparib in combination with pembrolizumab in patients with advanced melanoma with homologous recombin2020
2020-12-01Genentech, Inc.$5,615Research paymentCash or cash equivalent DrugPH 1A SAD OF GDC 0134 IN ALS PATIENTS2020
2020-12-01Genentech, Inc.$1,235Research paymentCash or cash equivalent DrugPH 1A SAD OF GDC 0134 IN ALS PATIENTS2020
2020-12-01Merck Sharp & Dohme LLC$1,000Research paymentCash or cash equivalentMK-7339 Drug, ONCOLOGYA Phase 2 Study of Olaparib in Combination with Pembrolizumab in Participants with Previously Treated, Homologous Recomb2020
2020-11-30Vanda Pharmaceuticals Inc.$2,530Research paymentCash or cash equivalentSTUDY TO ASSESS THE EFFICACY OF VLY-686 IN RELIEVING SYMPTOMS OF GASTROPARESIS2020
2020-11-24Genentech, Inc.$2,970Research paymentCash or cash equivalentNon-Covered Product Drug, NoneGDC0068 COMB W TAXOTERE OR FOLFOX2020
2020-11-20Genentech, Inc.$4,398Research paymentCash or cash equivalentAvastin Biological, BioOncologyA PHASE III OPEN LABEL RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF ATEZOLIZUMAB IN COMB2020
2020-11-19Merck Sharp & Dohme LLC$519Research paymentIn-kind items and servicesLENVIMA Drug, ONCOLOGYA Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib Versu2020
2020-11-18Gilead Sciences, Inc.$5,189Research paymentCash or cash equivalentA Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilof2020
2020-11-18Medtronic Vascular, Inc.$650Research paymentCash or cash equivalentCoreValve Evolut Device, Transcatheter Valve SystemsOptimize Pro2020
2020-11-17Merck Sharp & Dohme LLC$16,641Research paymentCash or cash equivalentLENVIMA Drug, ONCOLOGYA Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib Versu2020
2020-11-17Genentech, Inc.$1,325Research paymentCash or cash equivalentNon-Covered Product Drug, NoneGDC0068 COMB W TAXOTERE OR FOLFOX2020
2020-11-16Merck Sharp & Dohme LLC$26,055Research paymentIn-kind items and servicesLENVIMA Drug, ONCOLOGYA Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib Versu2020
2020-11-16F. Hoffmann-La Roche AG$500Research paymentCash or cash equivalentCOTELLIC Drug, BioOncologyPH 1B STUDY OF COBIMETINIB AND PARP INHIBITOR WITH OR WITHOUT ATEZOLIZUMAB IN PSOC2020
2020-11-05Genentech, Inc.$1,532Research paymentCash or cash equivalentAvastin Biological, BioOncologyA PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM2020
2020-11-04Genentech, Inc.$48,211Research paymentCash or cash equivalent DrugPH 1A SAD OF GDC 0134 IN ALS PATIENTS2020
2020-10-28Gyrus ACMI, Inc.$4,500Research paymentCash or cash equivalentSVS Device, EndoTherapyValves Against Standard Therapy2020
2020-10-28Gyrus ACMI, Inc.$500Research paymentCash or cash equivalentSVS Device, EndoTherapyValves Against Standard Therapy2020
2020-10-27Merck Sharp & Dohme LLC$9,910Research paymentCash or cash equivalentLENVIMA Drug, ONCOLOGYA Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib Versu2020
2020-10-27Merck Sharp & Dohme LLC$115Research paymentIn-kind items and servicesLENVIMA Drug, ONCOLOGYA Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib Versu2020
2020-10-26Merck Sharp & Dohme LLC$26,055Research paymentIn-kind items and servicesLENVIMA Drug, ONCOLOGYA Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib Versu2020
2020-10-26Genentech, Inc.$1,627Research paymentCash or cash equivalentAvastin Biological, BioOncologyA PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM2020
2020-10-22Genentech, Inc.$4,697Research paymentCash or cash equivalentNon-Covered Product Drug, NoneTENECTEPLASE IN STROKE PATIENTS BETWEEN 4 5 AND 24 HOURS2020
2020-10-22PFIZER INC.$2,350Research paymentCash or cash equivalentBAVENCIO Drug, ONCOLOGYA RANDOMIZED OPENLABEL MULTICENTER PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AVELUMAB IN COMBINATION WITH CHE2020
2020-10-21Gilead Sciences, Inc.$3,757Research paymentCash or cash equivalentA Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilof2020
2020-10-19Novocure Inc.$27,650Research paymentCash or cash equivalentOptune Device, OncologyEF-28 Engot -ov50/ INNOVATE-3: Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields, 200kHz) Concomi2020
2020-10-19Genentech, Inc.$1,550Research paymentCash or cash equivalent DrugPH 1A SAD OF GDC 0134 IN ALS PATIENTS2020
2020-10-13Merck Sharp & Dohme LLC$1,000Research paymentCash or cash equivalentMK-7339 Drug, ONCOLOGYA Phase 2 Study of Olaparib in Combination with Pembrolizumab in Participants with Previously Treated, Homologous Recomb2020
2020-10-08Penumbra, Inc.$1,725Research paymentCash or cash equivalent3D Revascularization Device, NeurointerventionCOMPLETE2020
2020-10-06Takeda Pharmaceuticals U.S.A., Inc.$280Research paymentCash or cash equivalentHYQVIA Biological, IMMUNOLOGYTHIS IS A PHASE III, PROSPECTIVE, MULTICENTER STUDY WITH TWO STUDY PARTS (EPOCHS) TO EVALUATE THE EFFICACY, SAFETY, AND 2020
2020-10-05Orion Corporation$8,480Research paymentCash or cash equivalentEffects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS2020
2020-10-05Orion Corporation$5,250Research paymentCash or cash equivalentEffects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS2020
2020-10-01Genentech, Inc.$18,008Research paymentCash or cash equivalentTECENTRIQ Biological, BioOncologyA PHASE III OF ATEZOLIZUMAB PLUS ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER2020
2020-10-01Genentech, Inc.$769Research paymentCash or cash equivalentAvastin Biological, BioOncologyA PHASE III OPEN LABEL RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF ATEZOLIZUMAB IN COMB2020
2020-09-29Merck Sharp & Dohme LLC$3,045Research paymentCash or cash equivalentMK-7339 Drug, ONCOLOGYA Phase 2 Study of Olaparib in Combination with Pembrolizumab in Participants with Previously Treated, Homologous Recomb2020
2020-09-24Merck Sharp & Dohme LLC$18,932Research paymentCash or cash equivalentLENVIMA Drug, ONCOLOGYA Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib Versu2020
2020-09-24Merck Sharp & Dohme LLC$500Research paymentCash or cash equivalentLENVIMA Drug, ONCOLOGYA Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib Versu2020
2020-09-23Gilead Sciences, Inc.$27Research paymentCash or cash equivalentA Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilof2020
2020-09-18Genentech, Inc.$4,600Research paymentCash or cash equivalent DrugPH 1A SAD OF GDC 0134 IN ALS PATIENTS2020
2020-09-17Vanda Pharmaceuticals Inc.$583Research paymentCash or cash equivalentSTUDY TO ASSESS THE EFFICACY OF VLY-686 IN RELIEVING SYMPTOMS OF GASTROPARESIS2020
2020-09-17Merck Sharp & Dohme LLC$537Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYAdjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab MK-3475 versus placebo after complete resection 2020
2020-09-16Genentech, Inc.$10,000Research paymentCash or cash equivalentNon-Covered Product Drug, NoneABIRATERONE PLUS GDC 0068 OR GDC 0980 IN CRPC2020
2020-09-16Novocure Inc.$1,589Research paymentCash or cash equivalentOptune Device, OncologyEF-28 Engot -ov50/ INNOVATE-3: Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields, 200kHz) Concomi2020
2020-09-16Novocure Inc.$572Research paymentCash or cash equivalentOptune Device, OncologyEF-28 Engot -ov50/ INNOVATE-3: Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields, 200kHz) Concomi2020
2020-09-16Genentech, Inc.$500Research paymentCash or cash equivalentNon-Covered Product Drug, NoneABIRATERONE PLUS GDC 0068 OR GDC 0980 IN CRPC2020
2020-09-16Genentech, Inc.$500Research paymentCash or cash equivalentNon-Covered Product Drug, NoneABIRATERONE PLUS GDC 0068 OR GDC 0980 IN CRPC2020
2020-09-14Merck Sharp & Dohme LLC$26,055Research paymentIn-kind items and servicesLENVIMA Drug, ONCOLOGYA Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib Versu2020
2020-09-14Takeda Pharmaceuticals U.S.A., Inc.$5,900Research paymentCash or cash equivalentA STUDY OF SAPANISERTIB, COMBINATION OF SAPANISERTIB WITH MLN1117, PACLITAXEL AND COMBINATION OF SAPANISERTIB WITH PACLI2020
2020-09-14Takeda Pharmaceuticals U.S.A., Inc.$4,271Research paymentCash or cash equivalentA STUDY OF SAPANISERTIB, COMBINATION OF SAPANISERTIB WITH MLN1117, PACLITAXEL AND COMBINATION OF SAPANISERTIB WITH PACLI2020
2020-09-11Genentech, Inc.$1,653Research paymentCash or cash equivalentHerceptin Biological, BioOncologyPERJETA SAFETY STUDY IN NEO ADJUVANT BC2020
2020-09-10Genentech, Inc.$2,200Research paymentCash or cash equivalent DrugPH 1A SAD OF GDC 0134 IN ALS PATIENTS2020
2020-09-03MITSUBISHI TANABE PHARMA DEVELOPMENT AMERICA, INC.$11,800Research paymentCash or cash equivalentSAFETY STUDY OF ORAL EDARAVONE ADMINISTERED IN SUBJECTS WITH ALS2020
2020-09-03Intercept Pharmaceuticals, Inc.$750Research paymentCash or cash equivalentOCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY10118662020
2020-08-27Genentech, Inc.$12,615Research paymentCash or cash equivalentAvastin Biological, BioOncologyA PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM2020
2020-08-27Genentech, Inc.$425Research paymentCash or cash equivalentHerceptin Biological, BioOncologyPERJETA SAFETY STUDY IN NEO ADJUVANT BC2020
2020-08-26Merck Sharp & Dohme LLC$77Research paymentIn-kind items and servicesLENVIMA Drug, ONCOLOGYA Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib Versu2020
2020-08-25Genentech, Inc.$750Research paymentCash or cash equivalentNon-Covered Product Drug, NoneTENECTEPLASE IN STROKE PATIENTS BETWEEN 4 5 AND 24 HOURS2020
2020-08-25Merck Sharp & Dohme LLC$8Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYAdjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab MK-3475 versus placebo after complete resection 2020
2020-08-21Genentech, Inc.$4,355Research paymentCash or cash equivalentNon-Covered Product Drug, NoneGDC0068 COMB W TAXOTERE OR FOLFOX2020
2020-08-20Merck Sharp & Dohme LLC$3,788Research paymentCash or cash equivalentLENVIMA Drug, ONCOLOGYA Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib Versu2020
2020-08-19Medtronic Vascular, Inc.$12,500Research paymentCash or cash equivalentCoreValve Evolut Device, Transcatheter Valve SystemsOptimize Pro2020
2020-08-18Genentech, Inc.$5,959Research paymentCash or cash equivalentNon-Covered Product Drug, NoneGDC0068 COMB W TAXOTERE OR FOLFOX2020
2020-08-18Genentech, Inc.$4,866Research paymentCash or cash equivalentNon-Covered Product Drug, NoneGDC0068 COMB W TAXOTERE OR FOLFOX2020
2020-08-18Genentech, Inc.$1,804Research paymentCash or cash equivalentNon-Covered Product Drug, NoneGDC0068 COMB W TAXOTERE OR FOLFOX2020
2020-08-18Genentech, Inc.$1,804Research paymentCash or cash equivalentNon-Covered Product Drug, NoneGDC0068 COMB W TAXOTERE OR FOLFOX2020
2020-08-18Genentech, Inc.$1,530Research paymentCash or cash equivalentNon-Covered Product Drug, NoneGDC0068 COMB W TAXOTERE OR FOLFOX2020
2020-08-18Genentech, Inc.$1,530Research paymentCash or cash equivalentNon-Covered Product Drug, NoneGDC0068 COMB W TAXOTERE OR FOLFOX2020
2020-08-18Genentech, Inc.$1,530Research paymentCash or cash equivalentNon-Covered Product Drug, NoneGDC0068 COMB W TAXOTERE OR FOLFOX2020
2020-08-18Genentech, Inc.$1,530Research paymentCash or cash equivalentNon-Covered Product Drug, NoneGDC0068 COMB W TAXOTERE OR FOLFOX2020
2020-08-18Genentech, Inc.$1,530Research paymentCash or cash equivalentNon-Covered Product Drug, NoneGDC0068 COMB W TAXOTERE OR FOLFOX2020
2020-08-18Genentech, Inc.$1,027Research paymentCash or cash equivalentNon-Covered Product Drug, NoneGDC0068 COMB W TAXOTERE OR FOLFOX2020
2020-08-18Merck Sharp & Dohme LLC$400Research paymentCash or cash equivalentLENVIMA Drug, ONCOLOGYA Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib Versu2020
2020-08-12Gilead Sciences, Inc.$10,303Research paymentCash or cash equivalentSTELLAR-4 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonserti2020
2020-08-06Merck Sharp & Dohme LLC$26,055Research paymentIn-kind items and servicesLENVIMA Drug, ONCOLOGYA Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib Versu2020
2020-08-06VIVUS LLC$298Research paymentCash or cash equivalentPANCREAZE Drug, CYSTIC FIBROSISLong-term Study in US Cystic Fibrosis2020
2020-08-04Merck Sharp & Dohme LLC$500Research paymentCash or cash equivalentMK-7339 Drug, ONCOLOGYA Phase 2 Study of Olaparib in Combination with Pembrolizumab in Participants with Previously Treated, Homologous Recomb2020
2020-07-30Merck Sharp & Dohme LLC$800Research paymentCash or cash equivalentLENVIMA Drug, ONCOLOGYA Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib Versu2020
2020-07-28Genentech, Inc.$3,750Research paymentCash or cash equivalentAvastin Biological, BioOncologyA PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM2020
2020-07-28Merck Sharp & Dohme LLC$20Research paymentIn-kind items and servicesLENVIMA Drug, ONCOLOGYA Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib Versu2020
2020-07-22Gilead Sciences, Inc.$9,527Research paymentCash or cash equivalentVeklury Drug, COVID-19The Simple Study in Coronavirus, Severe Subjects2020
2020-07-22Gilead Sciences, Inc.$4,100Research paymentCash or cash equivalentVeklury Drug, COVID-19The Simple Study in Coronavirus, Severe Subjects2020
2020-07-22Gilead Sciences, Inc.$2,235Research paymentCash or cash equivalentVeklury Drug, COVID-19The Simple Study in Coronavirus, Severe Subjects2020
2020-07-22Gilead Sciences, Inc.$1,788Research paymentCash or cash equivalentVeklury Drug, COVID-19The Simple Study in Coronavirus, Severe Subjects2020
2020-07-22Gilead Sciences, Inc.$1,341Research paymentCash or cash equivalentVeklury Drug, COVID-19The Simple Study - Subjects with Mild to Moderate Coronavirus Infection2020
2020-07-22Gilead Sciences, Inc.$447Research paymentCash or cash equivalentVeklury Drug, COVID-19The Simple Study in Coronavirus, Severe Subjects2020
2020-07-22Gilead Sciences, Inc.$447Research paymentCash or cash equivalentVeklury Drug, COVID-19The Simple Study - Subjects with Mild to Moderate Coronavirus Infection2020
2020-07-21Merck Sharp & Dohme LLC$6,946Research paymentCash or cash equivalentLENVIMA Drug, ONCOLOGYA Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib Versu2020
2020-07-16VIVUS LLC$750Research paymentCash or cash equivalentPANCREAZE Drug, CYSTIC FIBROSISLong-term Study in US Cystic Fibrosis2020
2020-07-06F. Hoffmann-La Roche AG$3,500Research paymentCash or cash equivalentCOTELLIC Drug, BioOncologyPH 1B STUDY OF COBIMETINIB AND PARP INHIBITOR WITH OR WITHOUT ATEZOLIZUMAB IN PSOC2020
2020-07-03Genentech, Inc.$18,407Research paymentCash or cash equivalent DrugPH 1A SAD OF GDC 0134 IN ALS PATIENTS2020
2020-07-02Genentech, Inc.$819Research paymentCash or cash equivalentNon-Covered Product Drug, NoneTENECTEPLASE IN STROKE PATIENTS BETWEEN 4 5 AND 24 HOURS2020
2020-06-26ARRAY BIOPHARMA INC$1,300Research paymentCash or cash equivalentBRAFTOVI Drug, ONCOLOGYA PHASE 2 OPENLABEL RANDOMIZED MULTICENTER TRIAL OF ENCORAFENIB BINIMETINIB EVALUATING A STANDARDDOSE AND A HIGHDOSE RE2020
2020-06-25Genentech, Inc.$9,384Research paymentCash or cash equivalentNon-Covered Product Drug, NoneTENECTEPLASE IN STROKE PATIENTS BETWEEN 4 5 AND 24 HOURS2020
2020-06-25Merck Sharp & Dohme LLC$805Research paymentIn-kind items and servicesLENVIMA Drug, ONCOLOGYA Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib Versu2020
2020-06-22Merck Sharp & Dohme LLC$13,027Research paymentIn-kind items and servicesLENVIMA Drug, ONCOLOGYA Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib Versu2020
2020-06-22Merck Sharp & Dohme LLC$8,314Research paymentCash or cash equivalentLENVIMA Drug, ONCOLOGYA Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib Versu2020
2020-06-19Genentech, Inc.$1,550Research paymentCash or cash equivalent DrugPH 1A SAD OF GDC 0134 IN ALS PATIENTS2020
2020-06-18Intercept Pharmaceuticals, Inc.$8,260Research paymentCash or cash equivalentOCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY10118662020
2020-06-17Gilead Sciences, Inc.$125,708Research paymentCash or cash equivalentVeklury Drug, COVID-19The Simple Study in Coronavirus, Severe Subjects2020
2020-06-17Gilead Sciences, Inc.$125,258Research paymentCash or cash equivalentVeklury Drug, COVID-19The Simple Study in Coronavirus, Severe Subjects2020
2020-06-17Gilead Sciences, Inc.$85,187Research paymentCash or cash equivalentVeklury Drug, COVID-19The Simple Study in Coronavirus, Severe Subjects2020
2020-06-17Gilead Sciences, Inc.$55,218Research paymentCash or cash equivalentVeklury Drug, COVID-19The Simple Study in Coronavirus, Severe Subjects2020
2020-06-17Gilead Sciences, Inc.$44,563Research paymentCash or cash equivalentVeklury Drug, COVID-19The Simple Study - Subjects with Mild to Moderate Coronavirus Infection2020
2020-06-17Gilead Sciences, Inc.$38,415Research paymentCash or cash equivalentVeklury Drug, COVID-19The Simple Study - Subjects with Mild to Moderate Coronavirus Infection2020
2020-06-17Gilead Sciences, Inc.$38,030Research paymentCash or cash equivalentVeklury Drug, COVID-19The Simple Study in Coronavirus, Severe Subjects2020
2020-06-17Gilead Sciences, Inc.$1,879Research paymentCash or cash equivalentVeklury Drug, COVID-19The Simple Study - Subjects with Mild to Moderate Coronavirus Infection2020
2020-06-09Merck Sharp & Dohme LLC$4,083Research paymentCash or cash equivalentLENVIMA Drug, ONCOLOGYA Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib Versu2020
2020-06-03Gilead Sciences, Inc.$8,800Research paymentCash or cash equivalentA Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilof2020
2020-06-01Genentech, Inc.$7,957Research paymentCash or cash equivalentNon-Covered Product Drug, NonePHASE III IPATASERTIB PLUS ABIRATERON IN MCRPC 1ST LINE2020
2020-06-01Takeda Pharmaceuticals U.S.A., Inc.$5,000Research paymentCash or cash equivalentHYQVIA Biological, IMMUNOLOGYTHIS IS A PHASE III, PROSPECTIVE, MULTICENTER STUDY WITH TWO STUDY PARTS (EPOCHS) TO EVALUATE THE EFFICACY, SAFETY, AND 2020
2020-06-01Takeda Pharmaceuticals U.S.A., Inc.$4,119Research paymentCash or cash equivalentHYQVIA Biological, IMMUNOLOGYTHIS IS A PHASE III, PROSPECTIVE, MULTICENTER STUDY WITH TWO STUDY PARTS (EPOCHS) TO EVALUATE THE EFFICACY, SAFETY, AND 2020
2020-06-01Takeda Pharmaceuticals U.S.A., Inc.$3,500Research paymentCash or cash equivalentHYQVIA Biological, IMMUNOLOGYTHIS IS A PHASE III, PROSPECTIVE, MULTICENTER STUDY WITH TWO STUDY PARTS (EPOCHS) TO EVALUATE THE EFFICACY, SAFETY, AND 2020
2020-06-01Takeda Pharmaceuticals U.S.A., Inc.$1,500Research paymentCash or cash equivalentHYQVIA Biological, IMMUNOLOGYTHIS IS A PHASE III, PROSPECTIVE, MULTICENTER STUDY WITH TWO STUDY PARTS (EPOCHS) TO EVALUATE THE EFFICACY, SAFETY, AND 2020
2020-06-01Takeda Pharmaceuticals U.S.A., Inc.$1,200Research paymentCash or cash equivalentHYQVIA Biological, IMMUNOLOGYTHIS IS A PHASE III, PROSPECTIVE, MULTICENTER STUDY WITH TWO STUDY PARTS (EPOCHS) TO EVALUATE THE EFFICACY, SAFETY, AND 2020
2020-06-01Takeda Pharmaceuticals U.S.A., Inc.$750Research paymentCash or cash equivalentHYQVIA Biological, IMMUNOLOGYTHIS IS A PHASE III, PROSPECTIVE, MULTICENTER STUDY WITH TWO STUDY PARTS (EPOCHS) TO EVALUATE THE EFFICACY, SAFETY, AND 2020
2020-06-01Takeda Pharmaceuticals U.S.A., Inc.$550Research paymentCash or cash equivalentHYQVIA Biological, IMMUNOLOGYTHIS IS A PHASE III, PROSPECTIVE, MULTICENTER STUDY WITH TWO STUDY PARTS (EPOCHS) TO EVALUATE THE EFFICACY, SAFETY, AND 2020
2020-05-28Genentech, Inc.$3,750Research paymentCash or cash equivalentNon-Covered Product Drug, NoneTENECTEPLASE IN STROKE PATIENTS BETWEEN 4 5 AND 24 HOURS2020
2020-05-28Intercept Pharmaceuticals, Inc.$3,152Research paymentCash or cash equivalentOCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY10118662020
2020-05-28Merck Sharp & Dohme LLC$1,944Research paymentCash or cash equivalentMK-7339 Drug, ONCOLOGYA Phase 2 Study of Olaparib in Combination with Pembrolizumab in Participants with Previously Treated, Homologous Recomb2020
2020-05-20Gilead Sciences, Inc.$57,801Research paymentCash or cash equivalentVeklury Drug, COVID-19The Simple Study - Subjects with Mild to Moderate Coronavirus Infection2020
2020-05-20Gilead Sciences, Inc.$46,218Research paymentCash or cash equivalentVeklury Drug, COVID-19The Simple Study in Coronavirus, Severe Subjects2020
2020-05-20Gilead Sciences, Inc.$27,015Research paymentCash or cash equivalentVeklury Drug, COVID-19The Simple Study in Coronavirus, Severe Subjects2020
2020-05-20Gilead Sciences, Inc.$17,547Research paymentCash or cash equivalentVeklury Drug, COVID-19The Simple Study in Coronavirus, Severe Subjects2020
2020-05-20Gilead Sciences, Inc.$10,201Research paymentCash or cash equivalentVeklury Drug, COVID-19The Simple Study - Subjects with Mild to Moderate Coronavirus Infection2020
2020-05-20Gilead Sciences, Inc.$10,201Research paymentCash or cash equivalentVeklury Drug, COVID-19The Simple Study in Coronavirus, Severe Subjects2020
2020-05-20Gilead Sciences, Inc.$10,131Research paymentCash or cash equivalentVeklury Drug, COVID-19The Simple Study in Coronavirus, Severe Subjects2020
2020-05-20Gilead Sciences, Inc.$8,079Research paymentCash or cash equivalentVeklury Drug, COVID-19The Simple Study in Coronavirus, Severe Subjects2020
2020-05-20Gilead Sciences, Inc.$1,879Research paymentCash or cash equivalentVeklury Drug, COVID-19The Simple Study - Subjects with Mild to Moderate Coronavirus Infection2020
2020-05-19Genentech, Inc.$11,877Research paymentCash or cash equivalentAvastin Biological, BioOncologyA PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM2020
2020-05-13Gilead Sciences, Inc.$10,201Research paymentCash or cash equivalentVeklury Drug, COVID-19The Simple Study in Coronavirus, Severe Subjects2020
2020-05-13Gilead Sciences, Inc.$10,201Research paymentCash or cash equivalentVeklury Drug, COVID-19The Simple Study - Subjects with Mild to Moderate Coronavirus Infection2020
2020-05-11Merck Sharp & Dohme LLC$13,027Research paymentIn-kind items and servicesLENVIMA Drug, ONCOLOGYA Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib Versu2020
2020-05-05Amgen Inc.$4,860Research paymentCash or cash equivalentIMLYGIC Biological, OncologyP1/3 talimogene laherparepvec + MK-3475 Combo melanoma2020
2020-05-01Genentech, Inc.$572Research paymentCash or cash equivalentAvastin Biological, BioOncologyA PHASE III OPEN LABEL RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF ATEZOLIZUMAB IN COMB2020
2020-04-27Merck Sharp & Dohme LLC$51Research paymentIn-kind items and servicesLENVIMA Drug, ONCOLOGYA Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib Versu2020
2020-04-20Gilead Sciences, Inc.$10,201Research paymentCash or cash equivalentVeklury Drug, COVID-19The Simple Study - Subjects with Mild to Moderate Coronavirus Infection2020
2020-04-20Gilead Sciences, Inc.$10,201Research paymentCash or cash equivalentVeklury Drug, COVID-19The Simple Study in Coronavirus, Severe Subjects2020
2020-04-16Merck Sharp & Dohme LLC$4,583Research paymentCash or cash equivalentLENVIMA Drug, ONCOLOGYA Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib Versu2020
2020-04-16Intercept Pharmaceuticals, Inc.$2,250Research paymentCash or cash equivalentOCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY10118662020
2020-04-09Jenavalve Technology, Inc.$41,465Compensation for services other than consulting, including serving as faculty or as a speaker at a v (6 payments)Cash or cash equivalentJenaValve Pericardial TAVR System Device, Cardiology2020
2020-04-09Genentech, Inc.$11,096Research paymentCash or cash equivalentZelboraf Biological, BioOncologyPHASE III BRAF MEK COMBINATION2020
2020-04-06Gilead Sciences, Inc.$10,201Research paymentCash or cash equivalentVeklury Drug, COVID-19The Simple Study in Coronavirus, Severe Subjects2020
2020-04-06Gilead Sciences, Inc.$10,201Research paymentCash or cash equivalentVeklury Drug, COVID-19The Simple Study - Subjects with Mild to Moderate Coronavirus Infection2020
2020-04-01Genentech, Inc.$7,018Research paymentCash or cash equivalent DrugPH 1A SAD OF GDC 0134 IN ALS PATIENTS2020
2020-03-31Spiration, Inc.$992Research paymentCash or cash equivalentSpiration Valve System Device, EndoTherapy ProductsA Prospective, Randomized, Controlled Multicenter clinical Trial to Evaluate the Safety and Effectiveness of the IBV Val2020
2020-03-30Merck Sharp & Dohme LLC$16,239Research paymentIn-kind items and servicesLENVIMA Drug, ONCOLOGYA Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib Versu2020
2020-03-30Gilead Sciences, Inc.$10,201Research paymentCash or cash equivalentVeklury Drug, COVID-19The Simple Study in Coronavirus, Severe Subjects2020
2020-03-30Gilead Sciences, Inc.$10,201Research paymentCash or cash equivalentVeklury Drug, COVID-19The Simple Study - Subjects with Mild to Moderate Coronavirus Infection2020
2020-03-30Genentech, Inc.$2,021Research paymentCash or cash equivalentAvastin Biological, BioOncologyA PHASE III OPEN LABEL RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF ATEZOLIZUMAB IN COMB2020
2020-03-30Genentech, Inc.$1,000Research paymentCash or cash equivalentTECENTRIQ Biological, BioOncologyA PHASE III OF ATEZOLIZUMAB PLUS ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER2020
2020-03-26Merck Sharp & Dohme LLC$5,426Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYAdjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab MK-3475 versus placebo after complete resection 2020
2020-03-26Merck Sharp & Dohme LLC$696Research paymentIn-kind items and servicesLENVIMA Drug, ONCOLOGYA Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib Versu2020
2020-03-26CSL Behring$687Research paymentIn-kind items and servicesHaegarda Biological, ImmunologyA Double-blind, Randomized-withdrawal, Placebo-controlled Study to Evaluate the Efficacy and Safety of Human Plasma-deri2020
2020-03-24Genentech, Inc.$1,589Research paymentCash or cash equivalentNon-Covered Product Drug, NonePHASE III IPATASERTIB PLUS ABIRATERON IN MCRPC 1ST LINE2020
2020-03-24Astellas Pharma Global Development$1,000Research paymentCash or cash equivalentASTAGRAF XL Drug, IMMUNOLOGYASTAGRAF XL TO UNDERSTAND THE IMPACT OF IMMUNOSUPPRESSION ON DE NOVO DSA DEVELOPMENT AND CHRONIC IMMUNE ACTIVATION IN KI2020
2020-03-23Takeda Pharmaceuticals U.S.A., Inc.$8,469Research paymentCash or cash equivalentA STUDY OF SAPANISERTIB, COMBINATION OF SAPANISERTIB WITH MLN1117, PACLITAXEL AND COMBINATION OF SAPANISERTIB WITH PACLI2020
2020-03-21Amgen Inc.$4,977Research paymentCash or cash equivalentGALACTIC - HF2020
2020-03-20Amgen Inc.$5,449Research paymentCash or cash equivalentIMLYGIC Biological, OncologyP2 Neo-adjuvant melanoma2020
2020-03-20Genentech, Inc.$990Research paymentCash or cash equivalentNon-Covered Product Drug, NoneGDC0068 COMB W TAXOTERE OR FOLFOX2020
2020-03-18Gilead Sciences, Inc.$9,553Research paymentCash or cash equivalentSTELLAR-3 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonserti2020
2020-03-16Merck Sharp & Dohme LLC$1,590Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYAdjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab MK-3475 versus placebo after complete resection 2020
2020-03-09Roche Products Limited$2,961Research paymentCash or cash equivalentOCREVUS Biological, ImmunologyPHASE II STUDY IN RRMS2020
2020-03-02Genentech, Inc.$870Research paymentCash or cash equivalentTECENTRIQ Biological, BioOncologyA PHASE III OF ATEZOLIZUMAB PLUS ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER2020
2020-02-28PFIZER INC.$3,310Research paymentCash or cash equivalentBAVENCIO Drug, ONCOLOGYA RANDOMIZED OPENLABEL MULTICENTER PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AVELUMAB IN COMBINATION WITH CHE2020
2020-02-21Astellas Pharma Global Development$5,211Research paymentCash or cash equivalentASTAGRAF XL Drug, IMMUNOLOGYASTAGRAF XL TO UNDERSTAND THE IMPACT OF IMMUNOSUPPRESSION ON DE NOVO DSA DEVELOPMENT AND CHRONIC IMMUNE ACTIVATION IN KI2020
2020-02-20Intercept Pharmaceuticals, Inc.$8,610Research paymentCash or cash equivalentOCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY10118662020
2020-02-20Intercept Pharmaceuticals, Inc.$7,315Research paymentCash or cash equivalentOCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY10118662020
2020-02-20PFIZER INC.$2,161Research paymentCash or cash equivalentBAVENCIO Drug, ONCOLOGYA RANDOMIZED OPENLABEL MULTICENTER PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AVELUMAB MSB0010718C IN COMBINAT2020
2020-02-20PFIZER INC.$540Research paymentCash or cash equivalentBAVENCIO Drug, ONCOLOGYA RANDOMIZED OPENLABEL MULTICENTER PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AVELUMAB MSB0010718C IN COMBINAT2020
2020-02-20PFIZER INC.$250Research paymentCash or cash equivalentBAVENCIO Drug, ONCOLOGYA RANDOMIZED OPENLABEL MULTICENTER PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AVELUMAB MSB0010718C IN COMBINAT2020

The latest 200 records of 230.

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

San Francisco CountySan Francisco city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In San Francisco, CA, county San Francisco County, CA, state California; placed by its city name.

MeasurePlace (city or town)
San Francisco, CA
County
San Francisco County, CA
State
California
Population B01003830,235830,23539,287,377
Population, 2020 census P1873,965873,96539,538,223
Median age B0100240.040.037.9
Under 18 B0100113.7%13.7%22.0%
65 and over B0100117.6%17.6%15.7%
Households B11001363,970363,97013,548,091
Foreign born B0500234.0%34.0%27.0%
Median household income B19013$140,970$140,970$99,122
Median family income B19113$171,141$171,141$113,346
Per capita income B19301$92,289$92,289$49,513
Poverty rate B1700111.2%11.2%12.0%
Unemployment rate B230256.1%6.1%6.6%
Civilian labor force B23025507,262507,26220,068,466
Mean commute (minutes) B0801330.430.428.7
Bachelor's degree or higher B1500360.3%60.3%37.1%
Housing units B25001414,602414,60214,644,735
Owner-occupied B2500338.2%38.2%55.9%
Renters B2500361.8%61.8%44.1%
Median home value B25077$1,394,500$1,394,500$734,700
Median gross rent B25064$2,476$2,476$2,036
White, not Hispanic B0300236.8%36.8%33.8%
Black B030024.7%4.7%5.2%
Hispanic or Latino B0300216.2%16.2%40.2%
Asian B0300234.9%34.9%15.3%
American Indian and Alaska Native B030020.2%0.2%0.3%

Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); Unemployment rate: 5.5% in Sep 2016 to 5.0% in Oct 2026; low 3.8%, high 16.1% the state; Source: FRED, Federal Reserve Bank of St. Louis.

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in San Francisco, CA.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.